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Effects of ranolazine in patients with acute coronary syndrome and stable
angina according to whether they undergo percutaneous coronary
intervention: Observations from the MERLIN-TIMI 36 Trial
Benjamin Scirica1, Sabina Murphy1, Ewa Karwatowska-Prokopczuk2,
Gennyne Walker2, Luiz Belardinelli2, Ori Ben-Yehuda2, David Morrow1
1TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham
and Women’s Hospita, Boston, MA, 2Gilead Sciences, Forest City, CA
Background: Ranolazine is a late sodium current (late INa) inhibitor with anti-ischemic
effects that is indicated for the treatment of stable angina. Patients with a history stable
angina who subsequently are admitted with ACS are at particularly high risk of recurrent
ischemic events. We examined the 1-year incidence of recurrent CV events in patients
with prior angina who had PCI within 30 days of the index event and whether ranolazine
offered any incremental benefit compared to placebo.
Methods: 3565 patients in the MERLIN-TIMI 36 trial, which randomized patients with
NSTE-ACS to ranolazine vs. placebo, reported a history of prior stable angina. The
primary endpoint was the composite of CV death, MI, or recurrent ischemia (RI) defined
as ischemia w/ ECG changes, leading to hospitalization, prompting revascularization, or
worsening of stable angina prompting intensification of therapy.
Results: In this cohort of patients with prior angina presenting with NSTEACS, 914
patients underwent PCI within 30 days of randomization. Overall, patients who underwent
PCI had lower rates of CV death, but higher rates of RI and MI than patients who did not
undergo PCI. Ranolazine reduced the risk of RI regardless of whether patients did or did
not have PCI (21.3 v. 29.8%, HR 0.71, p0.011 and 14.7 v. 18.2%, HR 0.81, p0.03).
Ranolazine significantly reduced the risk of the primary endpoint, CV death, and RI
leading to revascularization in patients who underwent PCI, whereas there was no benefit
among patients who did not undergo PCI.
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135 29.3% 164 38.8% 0.73 0.007 308 23.7% 339 26.3% 0.91 0.24 0.12
CV death 7 1.7% 17 3.8% 0.39 0.027 97 7.0% 84 6.3% 1.19 0.25 0.016
MI 46 9.9% 48 10.7% 0.89 0.58 100 7.7% 104 8.2% 0.98 0.9 0.71
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98 21.3% 122 29.8% 0.71 0.011 179 14.7 222 18.2% 0.81 0.03 0.43
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leading to
revasc
45 9.4% 72 16.8% 0.55 0.01 32 2.7% 39 2.9% 0.82 0.39 0.18
Conclusions: Regardless of whether patients underwent PCI or not for the treatment of
ACS, ranolazine reduced the risk of recurrent ischemia during the 1 year following
admission. In patients who did have PCI within 30 days of admission, rates of the primary
endpoint and recurrent ischemia were lower in patients treated with ranolazine.
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Triple Versus Dual Antiplatelet Therapy in Patients with Acute Myocardial
Infarction and Renal Insufficiency:Results from Korea Acute Myocardial
Infarction Registry
Sang Yup Lim1
1Korea University Ansan Hospital, Ansan, Korea, Republic of
Background: Whether triple antiplatelet therapy is superior or not to dual antiplatelet
therapy in patients with acute myocardial infarction (AMI) undergoing percutaneous
coronary intervention in the era of renal insufficiency remains unclear.
Methods: As a part of the Korea Acute Myocardial Infarction Registry (KAMIR), 2288
AMI patients with renal insufficiency (GFR 60 ml/min) received either dual (aspirin
plus clopidogrel; n1587) or triple (aspirin plus clopidogrel plus cilostazol; n701)
antiplatelet therapy. Major adverse cardiac event (MACE) at 1- month and 1-year were
compared between these two groups.
Results: Compared with the dual group, the triple group had a similar incidence of major
bleeding events but a significantly lower incidence of in-hospital mortality. MACE rate at
1 month was significantly higher in the dual group than that of triple (16.3 % vs. 11.1%,
p0.05), which was mainly due to death rather than re-PCI (12.9 % vs. 9.1%, p0.05).
However, MACE rate at 1-year and MACE free survival day was not different between
two groups.
Conclusions: In AMI patients with renal insufficiency, triple antiplatelet therapy exhibits
a favorable in-hospital and short-term MACE event, but no difference in 1-year MACE
free survival.
TCT-721
P2Y12 Reactivity units (PRU) to Predict Hyporesponsiveness to Clopidogrel in
Patients with Chest Pain with Prior History of Coronary Artery Stenting in
Emergency Department
Rakesh Sharma1, Stephen Erickson2, Rohit Sharma3, Hanumanth Reddy4,
Donald Voelker4, Harvinder Dod3, Vibhuti Singh5, james Marsh6
1University of Arkansas for Medical Sciences, El Dorado, AR, 2University of
Arkansas for Medical Sciences, Little Rock, AR, 3Medical Center of South
Arkansas, El Dorado, AR, 4University of Arkansas for Medical Sciences, El
Dorado, AR, 5University of South Florida, Tampa, FL, 6University of Arkansas for
Medical Sciences, Little Rock, AR
Background: Dual anti-platelet regimen has been shown to reduce major adverse
cardiovascular events (MACE) after percutaneous coronary interventions (PCI). Variable
response to clopidogrel can lead to pharmacodynamic failure, which may translate into
clinical failure. We conducted a study to evaluate factors associated with hyporespon-
siveness to clopidogrel with P2Y12 reactivity units by VerifyNow in previously stented
patients presenting to the emergency department (ED) with chest pain while they were on
dual anti-platelet regimen.
Methods: Hyporesponsiveness to clopidogrel was evaluated in a cohort of 531 consec-
utive patients with history of coronary artery stenting, presenting to ED with chest pain.
Patients were labeled hyporesponders if they had P2Y12 Reactivity Units (PRU)  230.
221 patients (41.6%) had PRU230. A multivariable logistic regression model was used
to determine the relationship between clopidogrel hyporesponsiveness and several
potential risk factors, including gender, age, race, type I diabetes, type II diabetes,
hypertension, smoking, chronic renal failure, and obesity.
Results: Out of this cohort of 531 patients, three predictors were statistically significant
at p0.05 (see table below): Type II diabetes (adjusted odds ratio, AOR2.109), black
race (AOR2.165), and female gender (AOR1.813). Age was a moderately significant
predictor (p0.058, AOR1.167 per decade).
Variable Estimate Std Error z value Pr(>|z|) AOR 95% CI
Gender
(female)
0.595 0.191 3.113 0.0019 1.813 1.248 2.641
Age (decades) 0.155 0.082 1.899 0.0575 1.167 0.996 1.372
Race (Black) 0.772 0.215 3.589 0.0003 2.165 1.423 3.312
Type I diabetes -0.109 0.692 -0.158 0.8747 0.897 0.212 3.432
Type II diabetes 0.746 0.206 3.618 0.0003 2.109 1.410 3.166
Hypertension -0.299 0.287 -1.041 0.2980 0.742 0.424 1.309
Smoking -0.038 0.202 -0.190 0.8496 0.962 0.648 1.431
Chronic renal
failure
0.110 0.233 0.475 0.6349 1.117 0.706 1.760
Obesity 0.015 0.194 0.076 0.9396 1.015 0.693 1.485
Conclusions: There is a high prevalence of clopidogrel hyporesponsiveness in patients
presenting with chest pain. Out of multiple potential risk factors, type II diabetes and black
race were the strongest predictors of clopidogrel hyporesponsiveness, followed by gender
and age.
TCT-722
Platelet Function Testing Predicts Bleeding In Patients Exposed To
Clopidogrel Undergoing Coronary Artery Bypass Grafting
Grant Reed1, Elaine Hoffman1, Amit Kumar2, Andrew Maree3, Dalton McLean4,
Jacki Buros1, Sary Aranki1, Prem Shekar1, Arvind Agnihotri2, Laura Williams1,
Kenneth Rosenfeld2, Christopher Cannon1
1Brigham and Women’s Hospital, Boston, MA, 2Massachusetts General Hospital,
Boston, MA, 3Waterford Regional Hospital, Waterford City, Ireland, 4LeBauer
Health Care, Greensboro, NC
Background: Clopidogrel use prior to coronary artery bypass grafting (CABG) is
associated with increased bleeding. Whether a bedside platelet function test can predict
bleeding in patients exposed to clopidogrel undergoing CABG is unknown. The aim of
the current study was to determine a level of platelet reactivity as measured by the
VerifyNow™ P2Y12 platelet function assay (Accumetrics, San Diego, CA) above which
CABG can be undertaken in such patients without increased bleeding.
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Methods: VERIFY Pre-Op TIMI 45 was a prospective study of 42 patients with
indications for coronary angiography subsequently referred for CABG. All patients were
therapeutic on clopidogrel. Platelet function was assessed with VerifyNow™ P2Y12
Reaction Units (PRU). Chest tube output within 24-hours of CABG was stratified by PRU
 208,  230, and  275. Results reported as meanSD.
Results: Median time from last clopidogrel dose to CABG was 4 days (range 1 to 9
days). Patients who held clopidogrel 4 days had lower PRU than those who held for
4 days (19084 vs. 27121 PRU; p0.015). Thresholds of PRU  208 or  275
correlated with less bleeding but did not reach significance (p0.20 and p0.39). Patients
with PRU  230 had significantly less chest tube output than those with PRU  230
(622220 vs. 1028676; p0.026) (Figure).
Conclusions: The VerifyNow™ P2Y12 platelet function assay can be used to predict
perioperative bleeding in patients exposed to clopidogrel undergoing CABG. A threshold
of 230 PRU is associated with less bleeding, and may assist clinicians in optimizing the
timing of surgery.
TCT-723
Transferring from Clopidogrel Loading Dose to Prasugrel Loading Dose in
Acute Coronary Syndrome Patients: High on-Treatment Platelet Reactivity
Analysis of the TRIPLET Trial
Jean Diodati1, Dominick Angiolillo2, Jorge Saucedo3, Tracy Cardillo4,
Joseph Jakubowski4, Carsten Henneges5, Mark Effron4, Fred Lipkin6,
Harold Fisher7
1Hôpital du Sacré-Coeur de Montréal, Montréal, QC, 2University of Florida
College of Medicine-Jacksonville, Jacksonville, United States, 3University of
Oklahoma Health Sciences Center, Oklahoma City, OK, 4Eli Lilly and Company,
Indianapolis, IN, 5Eli Lilly and Company, Bad Homburg, Germany, 6Daiichi
Sankyo, Inc., Parsippany, NJ, 7Eli Lilly and Company, Toronto, Ontario
Background: High on-treatment platelet reactivity (HPR) has been identified as an
independent risk factor for ischemic events in acute coronary syndrome (ACS) patients
(pts). In TRIPLET, ACS pts undergoing percutaneous coronary intervention (PCI) were
given a prasugrel (pras) loading dose (LD) with or without a prior clopidogrel (clop) LD.
An analysis of HPR was included.
Methods: TRIPLET was a randomized, double-blind study in ACS-PCI pts on aspirin
using VerifyNow P2Y12 assay to evaluate Pras with or without prior Clop in 3 arms: (1)
placebo (PBO) followed by Pras 60-mg LD (2) Clop 600-mg LD followed by Pras 30-mg
LD (3) Clop 600-mg LD followed by Pras 60-mg LD. Pts undergoing PCI received Pras
10-mg once daily (qd) for 2-4 days. HPR (P2Y12 Reaction Units [PRU] 240) were
evaluated in the pharmacodynamic population within 24 hrs following the PBO/Clop LD,
immediately prior to Pras LD and at 2, 6, 24, 72 hrs following Pras LDs.
Results: HPR following Clop was 58.5% in the combined Clop LD arms. No substantial
difference was noted when stratified by time between the Clop and Pras LDs ( 6hrs vs
6 hrs). At 6 hrs in the combined Pras LD arms, HPR was 7.1%, with 0% HPR by 72
hrs. Because a high number of HPR occurred in a single site, a statistical outlier analysis
was performed. When outliers were excluded, HPR occurred in 1.9% at 6 hours and in 0%
by 24 hrs.
Conclusions: In TRIPLET, pts with ACS intended for PCI showed a high prevalence of
HPR after Clop 600-mg LD, even when measured after 6 hrs. When Pras LD was added,
HPR decreased substantially by 6 hrs and was absent by 72 hrs.
TCT-724
Clopidogrel Loading doses result in Favourable Changes in Nitric Oxide (NO)
Metabolism in Patients with Stable Angina Undergoing Percutaneous
Coronary Intervention (PCI)
Richard Anderson1, Shantu Bundhoo2, Ewelina Sagan3, Phillip James3
1University Hospital of Wales, Cardiff, Wales, 2University Hospital of Wales,
Cardiff, South Glamorgan, 3Wales Heart Research Institute, Cardiff, Wales
Background: Clopidogrel loading dose of 600mg is used in patients undergoing PCI and
those treated for acute coronary syndromes. 600mg of clopidogrel can significantly inhibit
platelet inhibition within 2 hours but also improve endothelial dysfunction in stable CAD
patients via a mechanism independent of platelet function. We sought to study the effect
of both acute clopidogrel 600mg loading and chronic 75mg therapy on markers of NO
metabolism, vasodilatory effect and antioxidant status in these patients.
Methods: 58 CAD patients were recruited. In the clopidogrel naive group (36 subjects)
blood was taken before and 2h after 600mg dose of clopidogrel and 75mg aspirin
(ASA)who were attending for PCI for stable angina. We studied another cohort on chronic
ASA and clopidogrel 75mg (22 subjects) after 2 months of therapy. All plasma samples
were measured for NO metabolites (nitrite, nitrate and S-nitrosothiols), cGMP (a marker
of vasodilatory effect) and antioxidant capacity of the plasma (ORAC index). Pearson
correlation statistics were performed on all acute pre and post clopidogrel loading and
chronic therapy to explore the relationships seen in NO metabolites.
Results: 2 hours after clopidogrel 600mg dose, plasma nitrite was increased from
157.182.4 to 194.287.64 nM (p0.012), cGMP from 214.2124.4 to 231.5107.8
pmol/ml(p0.05) and ORAC index from 60.6611.45 to 64.1510.61%(p0.037).
Acute loading - the rise in cGMP was inversely related to the total antioxidant capacity
of the plasma (ORAC index)p0.0001 also the rise in nitrite with the increase in cGMP
p0.0043. There was a weaker correlation in the rise in nitrate as a consequence of
600mg with the rise in ORAC p0.0782. After chronic clopidogrel, nitrite was increased
from 157.182.4 to 254.3139.4nM(p0.0028), as well as cGMP from 214.2124.4 to
276.972.15pmol/ml(p0.05). In both acute and chronic groups RSNO (nitrosothiol)
was unchanged.
Conclusions: Patients receiving clopidogrel exhibit a time-proportional increase in NO
bioavailability and effective vasodilation. Clopidogrel has beneficial effects on redox
status 2 hours after 600mg. These results suggest non platelet - pleiotropic effects of
clopidogrel in CAD patients.
TCT-725
Point-of-Care Genetic Testing of Eleven CYP2C19 Single Nucleotide
Polymorphisms Identifies Extensive and Reduced Metabolizers of Clopidogrel
With High Accuracy in Patients With Coronary Artery Disease
David Erlinge1, Stefan James2, Suman Duvvuru3, Joseph Jakubowski3,
Henrik Wanger4, Christoph Varenhorst2, Udaya Tantry5, Patricia Brown3,
David Small3, Brian Moser3, Scott Sundseth6, Joseph Walker7, Kenneth Winters3,
Paul Gurbel8
1Lund University, Lund, Sweden, 2Uppsala Clinical Research Center, Uppsala,
Sweden, 3Eli Lilly and Company, Indianapolis, IN, 4Region Skåne, Lund, Sweden,
5Sinai Center for Thrombosis Research, Baltimore, MD, 6Cabernet
Pharmaceuticals, Chapel Hill, NC, 7Daiichi Sankyo, Inc., Edison, NJ, 8Sinai
Center for Thrombosis Research, Baltimore, United States
Background: The clinical use of genetic testing in ACS is limited by accessibility and
turn-around-time. Nanosphere Verigene® System is a novel point-of-care (POC) genetic
test analyzing 11 CYP2C19 variants within 3 hours. We evaluated the accuracy of the
method to identify extensive (EM) and reduced clopidogrel (clop) metabolizers (RM) in
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